Clinical Trial Update: Subconjunctival IVIg (Gamunex-C) Injection for Corneal Neovascularization and Inflammatory Conditions [Phase 1]

View source ↗

Summary

A Phase 1 trial evaluating subconjunctival intravenous immunoglobulin (Gamunex-C) for corneal neovascularization, corneal graft failure, and anterior segment in…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anterior Segment Inflammation
• Corneal Graft Failure
• Corneal Neovascularization

Drugs mentioned

• Gamunex-C (intravenous immunoglobulin) (intravenous immunoglobulin)

Snippet

Sponsor: University of Utah | Conditions: Corneal Neovascularization, Corneal Graft Failure | Phase 1 | Status: WITHDRAWN